4.6 Article

Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort

Journal

JACC: CARDIOONCOLOGY
Volume 4, Issue 1, Pages 98-109

Publisher

ELSEVIER
DOI: 10.1016/j.jaccao.2021.11.007

Keywords

cardio-oncology; comorbidity; cancer; heart failure; mortality

Funding

  1. Italian Ministry of Health [GR-2018-123656 61-CHANGE]
  2. Regional Healthcare Agency of Puglia Region (AReSS Puglia) [Ma 2528/7-1, SFB 894, TRR-219]
  3. Istituto di Ricerche Farmacologiche Mario Negri IRCCS [01EO1504]
  4. Barth Syndrome Foundation
  5. German Research Foundation
  6. German Federal Agency for Education and Research
  7. Barth Syndrome Foundation
  8. German Research Foundation
  9. German Federal Agency for Education and Research

Ask authors/readers for more resources

This study assessed the association between heart failure (HF) and cancer incidence and mortality in a community-based cohort. The results showed that HF was associated with an increased risk of cancer and cancer-related mortality, especially among individuals under 70 years old.
BACKGROUND Studies assessing whether heart failure (HF) is associated with cancer and cancer-related mortality have yielded conflicting results.OBJECTIVES This study assessed cancer incidence and mortality according to pre-existing HF in a community-based cohort.METHODS Among individuals $50 years of age from the Puglia region in Italy with administrative health data from 2002 to 2018, no cancer within 3 years before the baseline evaluation, and $5-year follow-up, the study matched 104,020 subjects with HF at baseline with 104,020 control subjects according to age, sex, drug-derived complexity index, Charlson comorbidity index, and follow-up duration. Cancer incidence and mortality were defined based on International Classification of Diseases-Ninth Revision codes in hospitalization records or death certificates.RESULTS The incidence rate of cancer in HF patients and control subjects was 21.36 (95% CI: 20.98-21.74) and 12.42 (95% CI: 12.14-12.72) per 1000 person-years, respectively, with the HR being 1.76 (95% CI: 1.71-1.81). Cancer mortality was also higher in HF patients than control subjects (HR: 4.11; 95% CI: 3.86-4.38), especially in those <70 years of age (HR: 7.54; 95% CI: 6.33-8.98 vs HR: 3.80; 95% CI: 3.44-4.19 for 70-79 years of age; and HR: 3.10; 95% CI: 2.81-3.43 for $80 years of age). The association between HF and cancer mortality was confirmed in a competing risk analysis (subdistribution HR: 3.48; 95% CI: 3.27-3.72). The HF-related excess risk applied to the majority of cancer types. Among HF patients, prescription of high-dose loop diuretic was associated with higher cancer incidence (HR: 1.11; 95% CI: 1.031.21) and mortality (HR: 1.35; 95% CI: 1.19-1.53). CONCLUSIONS HF is associated with an increased risk of cancer and cancer-related mortality, which may be heightened in decompensated states. (J Am Coll Cardiol CardioOnc 2022;4:98-109) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available